The ability to mount a prominent inflammatory response to bacterial pathogens confers an advantage in innate immune defense but may signal an increased risk of atherosclerosis. We determined whether ...
A phase II evaluation of pemetrexed (ALIMTA, LY231514, IND#40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group No significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results